Establishing best practise in the application of expert review of mutagenicity under ICH M7

Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships

Tatiana I. Netzeva, Andrew Worth, Tom Aldenberg et al. · Alternatives to Laboratory Animals · 2005 · 814 citations

Pharmacy, Pharmacology, Drug Design +9

Comparison of Different Approaches to Define the Applicability Domain of QSAR Models

Faizan Sahigara, Kamel Mansouri, Davide Ballabio et al. · Molecules · 2012 · 608 citations · Full text

Pharmacy, Medicinal Chemistry, Drug Design +15

A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity

Lutz Müller, Robert J. Mauthe, Christopher M. Riley et al. · Regulatory Toxicology and Pharmacology · 2006 · 461 citations

Pharmacy, Pharmaceutics, Toxicology +12

Mutagenicity of aliphatic epoxides

D. R. Wade, Subhash C. Airy, Joseph E. Sinsheimer · Mutation Research/Genetic Toxicology · 1978 · 156 citations · Full text

Pharmacy, Toxicology, Mechanisms Of Toxicity +6

Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities

Andreas Sutter, Alexander Amberg, Scott Boyer et al. · Regulatory Toxicology and Pharmacology · 2013 · 126 citations

Pharmacy, Chemistry, Toxicology +15